Across TCGA pan-cancer cohorts, SLC35E2A RNA is linked to patient survival in 20 of 34 cancer types, making it the most broadly survival-associated SLC35E2A data layer compared with 3 for mutation status.
The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher SLC35E2A RNA is associated with better disease-free survival. In most high-consensus cancer types, elevated SLC35E2A expression acts as an unfavorable survival marker, although some lineages such as HNSC and BRCA show a favorable association.
HNSC, THCA, and BRCA are the cancer types where SLC35E2A RNA most reproducibly stratifies survival.
RNA survival associations by lineage
Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.